Psychedelics for Mental Health and a Glimpse into the European Cannabis Market, Key Insights by Adam Isaac Miller | Jun 21/2020

Reading Time: 3 minutes

  1. The importance of standardization – Authorities across Europe have listed 114 products containing CBD in the European Union’s food-safety alert system since the start of last year, with data indicating that some countries are policing novel-food violations more frequently than others. This is an excellent example of the importance of harmonization of regulations across countries to ensure consumers are receiving safe products. The CBD products flagged in the food-alert system were most often cited for containing an “unauthorized novel food ingredient.” Other entries listed CBD as an “unauthorized feed additive” or flagged CBD products that contained THC. Authorities in Germany, Sweden, and Spain were the top whistleblowers for CBD novel food violations. Germany and Ireland had the most entries for THC notifications. Thank you to the wonderful team at Hemp Industry Daily for sharing this information.
  1. The EU, a giant avenue of potential – When it comes to the cannabis market, the EU is a large and growing market of consumers which doesn’t produce as much as it uses. It also still has several parts that haven’t legalized cannabis under any circumstances, medical or otherwise, leaving the door open for future expansion as laws loosen up across Europe in the next few years. Right now, while some European countries like Slovakia, Sweden, and Denmark are still pretty rigid with their cannabis laws, other countries like Spain, Italy, and Portugal are not. As of 2019, the biggest importer of cannabis oils of the EU Member States was Germany, as well as being the biggest exporter of cannabis oils to other countries. Material referenced from link
  1. Ego dissolution with psilocybin – There is growing interest in the therapeutic utility of psychedelic substances, like psilocybin, for disorders characterized by distortions of the self-experience, like depression. Accumulating preclinical evidence emphasizes the role of the glutamate system in the acute action of the drug on brain and behavior; however, this has never been tested in humans. Following a double-blind, placebo-controlled, parallel-group design, researchers utilized an ultra-high field multimodal brain imaging approach and demonstrated that psilocybin (0.17 mg/kg) induced region-dependent alterations in glutamate, which predicted distortions in the subjective experience of one’s self (ego dissolution). Whereas higher levels of medial prefrontal cortical glutamate were associated with negatively experienced ego dissolution, lower levels in hippocampal glutamate were associated with positively experienced ego dissolution. Such findings provide further insights into the underlying neurobiological mechanisms of the psychedelic, as well as the baseline, state. Importantly, they may also provide a neurochemical basis for therapeutic effects as witnessed in ongoing clinical trials. Material reference

Highlights of the Week:

  • Switzerland releases details on recreational cannabis experiment, but full legalisation likely years away

About Adam Isaac Miller:

Adam spent over 8 years building various B2B businesses within education, investment, and medicinal cannabis, with progressive roles including business development, strategy, product development and project management. He has consulted private and listed cannabis producers and ancillary businesses since 2015, as one of the early entrants and experts in the burgeoning Australian cannabis industry. Adam founded and currently sits on the board of The Medical Cannabis Council, Australia’s largest not-for-profit industry body. He is a frequent public speaker and publishes a widely read industry newsletter. Adam earned a Bachelor of Entrepreneurship from the Royal Melbourne Institute of Technology.

Adam has appeared in several major news outlets including the Sydney Morning Herald, The Australian Financial Review, Startup Smart, SBS, SkyNews, MJBizDaily, and other major publications.